Aethlon Medical Receives Ethics Board Approval To Add Second Site To Its Ongoing Clinical Trial Of Its Hemopurifier To Treat Severe COVID-19 In India
Aethlon Medical Receives Ethics Board Approval To Add Second Site To Its Ongoing Clinical Trial Of Its Hemopurifier To Treat Severe COVID-19 In India
Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier to treat severe COVID-19 in India.
MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.
"Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of MAMC as a second high quality clinical site may improve our enrollment of patients who go on to require ICU care for severe infection," commented Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical.
Aethlon Medical's clinical trial of the Hemopurifier in patients with SARS-CoV-2, or COVID-19, in the ICU with severe or life-threatening disease, is designed to enroll up to 15 patients at up to three centers throughout India. The initial site for the ongoing trial is Medanta Medicity Hospital in Gurgaon, India, and currently remains open for enrollment, with one patient treated to date.
Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier to treat severe COVID-19 in India.
專注於開發診斷和治療癌症和危及生命的傳染病產品的醫療治療公司Aethlon Medical, Inc.（納斯達克股票代碼：AEMD）今天宣佈，它已獲得毛拉納·阿扎德醫學院（MAMC）的倫理審查委員會（ERB）的批准，這是其正在印度治療嚴重 COVID-19 的臨床試驗的第二個地點。
MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.
MAMC 成立於 1958 年，位於印度新德里。MAMC 隸屬於德里大學，由德里政府運營。
"Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of MAMC as a second high quality clinical site may improve our enrollment of patients who go on to require ICU care for severe infection," commented Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical.
“需要住院的 COVID-19 感染病例繼續在印度發生。Aethlon Medical首席醫學官Steven LaRosa醫學博士評論說，增加MAMC作爲第二個高質量臨床中心可能會提高我們對因嚴重感染而需要重症監護的患者的入組人數。
Aethlon Medical's clinical trial of the Hemopurifier in patients with SARS-CoV-2, or COVID-19, in the ICU with severe or life-threatening disease, is designed to enroll up to 15 patients at up to three centers throughout India. The initial site for the ongoing trial is Medanta Medicity Hospital in Gurgaon, India, and currently remains open for enrollment, with one patient treated to date.
Aethlon Medical在重症監護病房對患有嚴重或危及生命的疾病的SARS-CoV-2或 COVID-19 患者進行的血清淨化器臨床試驗旨在在印度最多三個中心招收多達15名患者。正在進行的試驗的初始地點是印度古爾岡的Medanta Medicity醫院，目前仍在接受入組，迄今爲止已治療了一名患者。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧